NVCR
NovoCure Ltd
Halal Rating :
Last Price
$26.16
Last updated:
Market Cap
-
7D Change
-4.44%
1 Year Change
79.73%
Company Overview
Industries
Exchange
Next Earnings Date
NovoCure Limited is an oncology company developing a novel platform technology called Tumor Treating Fields (TTFields). This innovative therapy uses electric fields to disrupt cancer cell division. The company's primary product, Optune, is approved for treating glioblastoma (GBM) and malignant pleural mesothelioma (MPM). The company focuses on extending survival in some of the most aggressive forms of cancer through the development and commercialization of their TTFields therapy.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $155.09m | $187.19m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $150.36m | $183.94m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $138.5m | $180.02m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate NovoCure Ltd's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.